Your browser doesn't support javascript.
Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
Jeong, Hye Won; Kim, Se-Mi; Jung, Min Kyung; Noh, Ji Yun; Yoo, Ji-Seung; Kim, Eun-Ha; Kim, Young-Il; Yu, Kwangmin; Jang, Seung-Gyu; Gil, Juryeon; Casel, Mark Anthony; Rare, Rollon; Choi, Jeong Ho; Kim, Hee-Sung; Kim, Jun Hyoung; Um, Jihye; Kim, Chaeyoon; Kim, Yeonjae; Chin, Bum Sik; Jung, Sungmin; Choi, Jun Yong; Song, Kyoung-Ho; Kim, Yong-Dae; Park, Jun-Sun; Song, Joon Young; Shin, Eui-Cheol; Choi, Young Ki.
  • Jeong HW; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.
  • Kim SM; Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea.
  • Jung MK; The Center for Viral Immunology, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea.
  • Noh JY; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 08308, Republic of Korea.
  • Yoo JS; Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea.
  • Kim EH; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea.
  • Kim YI; Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea.
  • Yu K; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea.
  • Jang SG; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea; Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea.
  • Gil J; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea.
  • Casel MA; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea; Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea.
  • Rare R; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea; Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea.
  • Choi JH; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea.
  • Kim HS; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.
  • Kim JH; Department of Internal Medicine, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.
  • Um J; Public Health Research Institute, National Medical Center, Seoul 04564, Republic of Korea.
  • Kim C; The Center for Viral Immunology, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea.
  • Kim Y; Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul 04564, Republic of Korea.
  • Chin BS; Division of Infectious Diseases, Department of Internal Medicine, National Medical Center, Seoul 04564, Republic of Korea.
  • Jung S; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
  • Choi JY; Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.
  • Song KH; Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam 13620, Republic of Korea.
  • Kim YD; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea; Chungbuk Regional Cancer Center, Chungbuk National University Hospital, Cheongju 28644, Republic of Korea.
  • Park JS; Public Health Research Institute, National Medical Center, Seoul 04564, Republic of Korea.
  • Song JY; Division of Infectious Diseases, Department of Internal Medicine, Korea University College of Medicine, Seoul 08308, Republic of Korea. Electronic address: infection@korea.ac.kr.
  • Shin EC; The Center for Viral Immunology, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea. Electronic address:
  • Choi YK; College of Medicine and Medical Research Institute, Chungbuk National University, Cheongju 28644, Republic of Korea; Center for Study of Emerging and Re-emerging Viruses, Korea Virus Research Institute, Institute for Basic Science (IBS), Daejeon 34126, Republic of Korea. Electronic address: choiki55
Cell Rep Med ; 3(10): 100764, 2022 10 18.
Article in English | MEDLINE | ID: covidwho-2031747
ABSTRACT
Omicron has become the globally dominant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant, creating additional challenges due to its ability to evade neutralization. Here, we report that neutralizing antibodies against Omicron variants are undetected following COVID-19 infection with ancestral or past SARS-CoV-2 variant viruses or after two-dose mRNA vaccination. Compared with two-dose vaccination, a three-dose vaccination course induces broad neutralizing antibody responses with improved durability against different SARS-CoV-2 variants, although neutralizing antibody titers against Omicron remain low. Intriguingly, among individuals with three-dose vaccination, Omicron breakthrough infection substantially augments serum neutralizing activity against a broad spectrum of SARS-CoV-2 variants, including Omicron variants BA.1, BA.2, and BA.5. Additionally, after Omicron breakthrough infection, memorycells respond to the spike proteins of both ancestral and Omicron SARS-CoV-2 by producing cytokines with polyfunctionality. These results suggest that Omicron breakthrough infection following three-dose mRNA vaccination induces pan-SARS-CoV-2 immunity that may protect against emerging SARS-CoV-2 variants of concern.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Med Year: 2022 Document Type: Article